MX354125B - A combination of an opioid agonist and an opioid antagonist in the treatment of parkinson's disease. - Google Patents

A combination of an opioid agonist and an opioid antagonist in the treatment of parkinson's disease.

Info

Publication number
MX354125B
MX354125B MX2013007622A MX2013007622A MX354125B MX 354125 B MX354125 B MX 354125B MX 2013007622 A MX2013007622 A MX 2013007622A MX 2013007622 A MX2013007622 A MX 2013007622A MX 354125 B MX354125 B MX 354125B
Authority
MX
Mexico
Prior art keywords
opioid
parkinson
disease
treatment
combination
Prior art date
Application number
MX2013007622A
Other languages
Spanish (es)
Other versions
MX2013007622A (en
Inventor
Michael Hopp
Claudia Trenkwalder
Original Assignee
Euro Celtique Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43903970&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX354125(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa
Publication of MX2013007622A publication Critical patent/MX2013007622A/en
Publication of MX354125B publication Critical patent/MX354125B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Reproductive Health (AREA)
  • Psychology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention provides a pharmaceutical dosage form comprising an opioid agonist and an opioid antagonist for use in the treatment of Parkinson's disease. The present invention also refers to the use of an opioid agonist and an opioid antagonist in such a dosage form.
MX2013007622A 2010-12-28 2011-12-27 A combination of an opioid agonist and an opioid antagonist in the treatment of parkinson's disease. MX354125B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10197210 2010-12-28
PCT/EP2011/074103 WO2012089738A1 (en) 2010-12-28 2011-12-27 A combination of an opioid agonist and an opioid antagonist in the treatment of parkinson's disease

Publications (2)

Publication Number Publication Date
MX2013007622A MX2013007622A (en) 2013-12-06
MX354125B true MX354125B (en) 2018-02-14

Family

ID=43903970

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013007622A MX354125B (en) 2010-12-28 2011-12-27 A combination of an opioid agonist and an opioid antagonist in the treatment of parkinson's disease.

Country Status (19)

Country Link
US (1) US20140037729A1 (en)
EP (1) EP2658523A1 (en)
JP (2) JP5864606B2 (en)
KR (2) KR101618929B1 (en)
CN (1) CN103347495B (en)
AR (1) AR084620A1 (en)
AU (1) AU2011351447B2 (en)
BR (1) BR112013016862A2 (en)
CA (1) CA2822528C (en)
CL (1) CL2013001943A1 (en)
EA (1) EA025747B1 (en)
MX (1) MX354125B (en)
MY (1) MY162895A (en)
NZ (1) NZ612837A (en)
SG (1) SG191208A1 (en)
TW (2) TW201628618A (en)
UA (1) UA109301C2 (en)
WO (1) WO2012089738A1 (en)
ZA (1) ZA201304303B (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9901540B2 (en) 2010-05-10 2018-02-27 Euro-Celtique S.A. Combination of active loaded granules with additional actives
CA2798884C (en) 2010-05-10 2016-09-13 Euro-Celtique S.A. Manufacturing of active-free granules and tablets comprising the same
KR101618929B1 (en) * 2010-12-28 2016-05-09 유로-셀티큐 에스.에이. A combination of an opioid agonist and an opioid antagonist in the treatment of parkinson's disease
US10736889B2 (en) 2011-04-29 2020-08-11 Rutgers, The State University Of New Jersey Method of treating dyskinesia
PL2701707T3 (en) * 2011-04-29 2021-03-08 Rutgers, The State University Of New Jersey Method of treating dyskinesia
US9918980B2 (en) 2011-04-29 2018-03-20 Rutgers, The State University Of New Jersey Method of treating dyskinesia
WO2014004126A1 (en) * 2012-06-26 2014-01-03 Fleming C Andrew Treating postoperative nausea and vomiting
CN105517551A (en) 2013-07-23 2016-04-20 欧洲凯尔特公司 A combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation
BR112016009749A8 (en) * 2013-11-13 2018-01-30 Euro Celtique Sa hydromorphone and naloxone for treatment of pain and opioid intestinal dysfunction syndrome
CA2847781C (en) * 2014-03-28 2019-03-12 Purdue Pharma Reducing drug liking in a subject
US20150352099A1 (en) * 2014-06-04 2015-12-10 Mentinova Inc. Compositions and Methods of Reducing Sedation
EP3183232B1 (en) 2014-08-22 2023-05-03 The Arizona Board of Regents on behalf of The University of Arizona Substituted 1-arylethyl-4-acylaminopiperidine derivatives as opioid/alpha-adrenoreceptor modulators and method of their preparation
CA2974055A1 (en) * 2015-01-23 2016-07-28 Euro-Celtique S.A. A combination of hydromorphone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk forintestinal bacterial translocation
US20160256451A1 (en) * 2015-03-06 2016-09-08 Develco Pharma Schweiz Ag Dosage of naloxone
CA2986891C (en) * 2015-05-26 2022-01-04 Technophage, Investigacao E Desenvolvimento Em Biotecnologia, Sa Compositions for use in treating parkinson's disease and related disorders
WO2018055199A1 (en) * 2016-09-26 2018-03-29 Euro-Celtique S.A. Methods of treatment comprising administering a high daily dose of oxycodone and naloxone in a 2:1 weight ratio
WO2021087456A1 (en) * 2019-10-31 2021-05-06 Fung Constance H Methods, systems, and apparatus for tapering or uptitrating drug dosages

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4769372A (en) * 1986-06-18 1988-09-06 The Rockefeller University Method of treating patients suffering from chronic pain or chronic cough
OA12215A (en) * 2000-02-08 2006-05-09 Euro Celtique Sa Tamper-resistant oral opioid agonist formulations.
AU782523B2 (en) * 2000-07-13 2005-08-04 Euro-Celtique S.A. Salts and bases of 17-(cyclopropylmethyl)-4,5 alpha-epoxy-6-methylenemorphinan-3,14 diol for optimizing dopamine homeostasis during administration of opioid analgesics
DE60230632D1 (en) * 2001-07-18 2009-02-12 Euro Celtique Sa PHARMACEUTICAL COMBINATIONS OF OXYCODONE AND NALOXONE
US20060177381A1 (en) * 2002-02-15 2006-08-10 Howard Brooks-Korn Opiopathies
EP1604666A1 (en) * 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
EP1695700A1 (en) * 2005-02-28 2006-08-30 Euro-Celtique S.A. Dosage form containing oxycodone and naloxone
US20070232638A1 (en) * 2006-04-03 2007-10-04 Howard Brooks-Korn Opiopathies
WO2009132313A2 (en) * 2008-04-25 2009-10-29 Progenics Pharmaceuticals, Inc. Morphinan derivatives of organic and inorganic acids
EP2317991B1 (en) * 2008-07-07 2017-05-03 Euro-Celtique S.A. Use of opioid antagonists for treating urinary retention
MX347106B (en) * 2009-03-10 2017-04-12 Euro-Celtique S A * Immediate release pharmaceutical compositions comprising oxycodone and naloxone.
GB0909680D0 (en) * 2009-06-05 2009-07-22 Euro Celtique Sa Dosage form
KR101618929B1 (en) * 2010-12-28 2016-05-09 유로-셀티큐 에스.에이. A combination of an opioid agonist and an opioid antagonist in the treatment of parkinson's disease

Also Published As

Publication number Publication date
MY162895A (en) 2017-07-31
EA025747B1 (en) 2017-01-30
SG191208A1 (en) 2013-07-31
NZ612837A (en) 2014-11-28
TWI554271B (en) 2016-10-21
JP6074003B2 (en) 2017-02-01
EA201390977A1 (en) 2013-12-30
KR101632858B1 (en) 2016-06-22
KR20150076262A (en) 2015-07-06
MX2013007622A (en) 2013-12-06
JP5864606B2 (en) 2016-02-17
ZA201304303B (en) 2014-02-26
UA109301C2 (en) 2015-08-10
CN103347495A (en) 2013-10-09
JP2014501268A (en) 2014-01-20
TW201628618A (en) 2016-08-16
KR101618929B1 (en) 2016-05-09
BR112013016862A2 (en) 2016-10-04
EP2658523A1 (en) 2013-11-06
AR084620A1 (en) 2013-05-29
CA2822528A1 (en) 2012-07-05
CN103347495B (en) 2017-06-20
KR20130106431A (en) 2013-09-27
US20140037729A1 (en) 2014-02-06
WO2012089738A1 (en) 2012-07-05
CA2822528C (en) 2017-07-18
AU2011351447B2 (en) 2016-02-25
TW201302199A (en) 2013-01-16
JP2016040268A (en) 2016-03-24
AU2011351447A1 (en) 2013-07-25
CL2013001943A1 (en) 2013-11-29

Similar Documents

Publication Publication Date Title
MX2013007622A (en) A combination of an opioid agonist and an opioid antagonist in the treatment of parkinson's disease.
MY152279A (en) Immediate release pharmaceutical compositions comprising oxycodone and naloxone
IN2015KN00414A (en)
IN2012DN06720A (en)
MX2013011908A (en) Compositions and therapeutic uses of ikk-related kinase epsilon and tankbinding kinase 1 inhibitors.
MY163055A (en) Polycyclic antagonists of lysophosphatidic acid receptors
EA201400246A1 (en) NEW, NOT ALLOWING ABUSE USING PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF OPIOID DEPENDENCE
IN2012DN00754A (en)
MX2011008450A (en) Agonists and antagonists of the s1p5 receptor, and methods of uses thereof.
EP2406765A4 (en) Device for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated and methods for use thereof
EP2528603A4 (en) Pharmaceutical compositions for the treatment of pain and other indicatons
JO3078B1 (en) Morpholinothiazoles as alpha 7 positive allosteric modulators
IN2015DN01164A (en)
MX348933B (en) Compositions, dosage forms, and coadministration of an opioid agonist compound and an analgesic compound.
MX2016004741A (en) Pharmaceutical composition comprising a trpa1 antagonist and an analgesic agent.
TN2012000488A1 (en) Pharmaceutical compositions comprising hydromorphone and naloxone
EA201390653A1 (en) AA ANTAGONISTS AS AMPLIFIERS OF COGNITIVE AND MOTOR FUNCTIONS
PH12016500666A1 (en) Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome
PL2379066T3 (en) Use of opioid antagonists for the preparation of a medicament in the treatment of retinal degenerative diseases
HK1203391A1 (en) Administration of an antagonist of alpha 5 beta1 for anti- antiogenesis and cancer treatment 51
GB201210686D0 (en) V1B receptor antagonist for use in the treatment of patients having an elevated AVP level and/or an elevated copeptin level
SG11201406093VA (en) An h3 receptor antagonist for use in the treatment of alzheimer's disease
IN2014DN09359A (en)
MX2014014813A (en) Use of ghrelin receptor inverse agonists or antagonists for treating sleep disorders.
PH12014501390A1 (en) Novel therapeutic use of p75 receptor antagonists

Legal Events

Date Code Title Description
FG Grant or registration